Expression and role of connexin-based gap junctions in pulmonary inflammatory diseases

• Published in: Alimentary Pharmacology & Therapeutics (Suppl) Vol. 164; pp. 105 - 119
• Main Authors: Freund-Michel, Véronique, Muller, Bernard, Marthan, Roger, Savineau, Jean-Pierre, Guibert, Christelle
• Format: Journal Article
• Language: English
• Published: England 01.08.2016
• Subjects: Animals; Cell Communication - physiology; Connexins - drug effects; Connexins - metabolism; Disease Models, Animal; Gap Junctions - drug effects; Gap Junctions - metabolism; Glycyrrhetinic Acid - pharmacology; Human health and pathology; Humans; Inflammation - physiopathology; Life Sciences; Lung - physiopathology; Lung Diseases - physiopathology; Phosphorylation - physiology; Pulmonary Artery - physiopathology; Pulmonary Fibrosis - physiopathology; Connexins; Inflammation; Gap junctions; Lung
• ISSN: 0163-7258; 0953-0673; 1879-016X; 1365-2036
• DOI: 10.1016/j.pharmthera.2016.04.004

Connexins are transmembrane proteins that can generate intercellular communication channels known as gap junctions. They contribute to the direct movement of ions and larger cytoplasmic solutes between various cell types. In the lung, connexins participate in a variety of physiological functions, such as tissue homeostasis and host defence. In addition, emerging evidence supports a role for connexins in various pulmonary inflammatory diseases, such as asthma, pulmonary hypertension, acute lung injury, lung fibrosis or cystic fibrosis. In these diseases, the altered expression of connexins leads to disruption of normal intercellular communication pathways, thus contributing to various pathophysiological aspects, such as inflammation or tissue altered reactivity and remodeling. The present review describes connexin structure and organization in gap junctions. It focuses on connexins in the lung, including pulmonary bronchial and arterial beds, by looking at their expression, regulation and physiological functions. This work also addresses the issue of connexin expression alteration in various pulmonary inflammatory diseases and describes how targeting connexin-based gap junctions with pharmacological tools, synthetic blocking peptides or genetic approaches, may open new therapeutic perspectives in the treatment of these diseases.